Juvenile Macular Degeneration (Stargardt Disease) Pipeline Review, H1 2017 – Research and Markets

by Business Wire • 2017/04/06 • 0 Comments

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2017" report to their offering. Juvenile Macular Degeneration - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule t

← Viral Conjunctivitis Pipeline Review, H1 2017 Featuring Adenovir Pharma, Marinomed Biotechnologie, NanoViricides, Panoptes Pharma, Shire & Starpharma – Research and Markets

Imprimis enters licensing agreement for dry eye formulation →

Post navigation